Sinopharm Group Co. Ltd. disclosed board-level adjustments that will take effect on 18 August 2026:

• Strategy and Investment Committee – Executive Director Yang Binghua joins as a member, expanding executive participation in the Company’s strategic planning body.

• Audit Committee – Non-executive Directors Zu Jing and Wen Deyong have been appointed members, strengthening oversight of financial reporting and internal control.

• Nomination Committee – Non-executive Director Li Ying becomes a member, adding depth to director selection and succession planning deliberations.

• Legal, Compliance and ESG Committee – Non-executive Director Xing Yonggang joins as a member, enhancing governance and sustainability supervision.

Following these changes, Sinopharm’s board consists of 2 executive directors, 7 non-executive directors and 5 independent non-executive directors. Chairman Jin Bin issued the announcement from Shanghai on 18 August 2026.